Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Looking for a particular Immuneering Corporation employee's phone or email?
Immuneering Corporation Questions
The Immuneering Corporation annual revenue was $14.4 million in 2026.
Ben Zeskind is the Co-Founder and CEO of Immuneering Corporation.
60 people are employed at Immuneering Corporation.
Immuneering Corporation is based in Cambridge, Massachusetts.
The NAICS codes for Immuneering Corporation are [541713, 541, 54, 32, 325, 5417, 54171].
The SIC codes for Immuneering Corporation are [28, 283].
Top Immuneering Corporation Employees
-
Ben Zeskind
Co-Founder and CEO at Immuneering Corporation
New York, NY, US13 -
Sarah Kolitz
VP, Translational Medicine at Immuneering Corporation
Cambridge, MA, US24 -
44
-
Brett Hall
CSO at Immuneering Corporation
San Diego, CA, US23 -
25+
-
Harold Brakewood
Chief Business Officer at Immuneering Corporation
New York, NY, US5+5+ -
25+
-
Peter King
Vice President, Head of Discovery at Immuneering Corporation
San Diego, CA, US23 -
Jason Funt
VP, Translational Genomics at Immuneering Corporation
San Diego, CA, US24
Related Companies
